GH Research (GHRS) Non-Current Deferred Tax Liability (2024 - 2025)
GH Research (GHRS) posted quarterly Non-Current Deferred Tax Liability of $200000.0 for Q4 2025, down 81.82% year-over-year from $1.1 million in Q4 2024, and down 81.82% quarter-over-quarter from $1.1 million in Q4 2024.
GH Research (GHRS) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
GH Research's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $200000.0 for Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability fell 81.82% year-over-year to $200000.0; the TTM figure through Dec 2025 stood at $200000.0 (down 81.82% YoY), while the FY2025 annual figure was $200000.0, down 81.82% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at $200000.0, down from $1.1 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $1.1 million in Q4 2024, with the low at $200000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |